			PA-IOC
QUERY CONTROL FORM,			RTIS USE ONLY
Application No. 09/771.669	Prepared by	MB	Tracking Number <i>0599784</i> /
Examiner-GAU Page 1615	Date	9/28/04	Week Date 08/16/04
7 0	No. of queries	4	IPW(PUT4)

JACKET									
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449						
b. Applicant(s)	g. Disclaimer	I. Print Fig.	q. PTOL-85b						
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract						
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs						
e. Domestic Priority	j. Claims Allowed	o. PTO-892	1. Other Andex of claim						

SPECIFICATION	MESŞAGE,
a. Page Missing	O First column of index of claims is blank (claims renumbered
b. Text Continuity	box not marked).
c. Holes through Data	2) Continuing data is listed in mechacotion (Amolt, dated
d. Other Missing Text	06/09/04) but not shown on the palm/bibsheet.
e. Illegible Text	(3) Original claims 7 and 8 both depends on
f. Duplicate Text	original digim 24. please advise/correct daim
g. Brief Description	dependency.
h. Sequence Listing	(4) clean com of claims (dated 01/07/03, coded as REM.
i. Appendix	pages 6-8 are illegible - see affached. Please provide
j. Amendments	legible I clearer coples of claim 1/8thm.
k. Other	
CLAIMS	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	Themleyou_
d. Incorrect Numbering	initials Mit.
e. Index Disagrees	RESPONSE
f. Punctuation	
g. Amendments	
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
* Other illegible	
Claim listing	initials

- 1. A composition with synergistic anti-inflammatory properties for use in conditions induced by inflammatory disease-causing biomolecules released from mast cells by the activation and degranulation of said mast cells, comprising a non-bovine proteoglycan and unrefined kernel olive oil, and one or more of a D-bexosamine sulfate, a flavouoid, findenosylmethionine, and a histamine-1-receptor antagonist, in an appropriate excipient or yehicle for oral or topical administration.
- 2. The composition according to claim 1, wherein said proteoglycan is selected from the group consisting of non-bovine chondroitin sulfate, keratan sulfate, dermatan sulfate and hydronic acid.
- 3. The composition according to claim 2, wherein said chondroitin sulfate is derived from shark carrilage.
- 4. The composition according to claim 1, wherein said bexosamine sulfate is Deglacosamine sulfate.
- 5. The composition according to claim 1, wherein said flavouoid is selected from the group consisting of quercetin, myrisetin, genistein and kaempferol.
- 6. The composition according to claim 1, wherein said olive oil contains omega forty acids and alpha-tocopherol.
- 7. The composition according to claim 24, said composition being for oral use, comprising 300 mg each of non-bovine chondroitin sulfate C, quercetin and D-glucosamine sulfate, in kernel olive oil.
- 8. The composition according to claims 7 or 24, further comprising 100 mg of 3- adensylmethionine.
- 9. The composition according to claim 1, wherein said inflammatory disease is arthritis and said composition is contained in an ointment or cream for topical application, comprising, in mg%, chondroitin sulfate 0.05; unrefined kernel olive oil, 1-5; and one or more of: 3-glucosamine sulfate, 0.05; and quercetin, 0.03.
 - 10. The composition according to claim 9, further comprising diphenhydranine. 5mg%.
- 11. A composition according to claim 1, said composition consisting of a month wash composition, comprising chondroitin sulfate, 0.4 M; unrefined kernel olive oil 0.5-4.5 mg and one or more of D-glucosamine sulfate, 0.4 M; and quercetin, 0.3 M, in a month wash vehicle.



- 13. A composition according to claim 1, said composition consisting of a tooth paste, comprising, in mg%, chondroitin sulfate, 0.0 5; and unrefined kernel olive oil, 1-5; and one or more of D-glucosamine sulfate, 0.05; and quercetin, 0.03; in a tooth paste vehicle.
- 13. A composition according to claim 1, said composition consisting of a subserven composition, comprising, in mg%, chondroitin sulfate, 0.05, and unrefined kernel oil 4-5; and one or more of D-glucosamine sulfate, 0.05; quercetin, 0.03; and titanium dioxide, 3-5; in a sun screen vehicle.
- wherein said inflammatory disease results from biomolecules secreted from activated and degranulated mast cells, said inflammatory disease being selected from the group consisting of asteoarthritis, cancer, fibromyalgia, atherosclerosis, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, migraines, angina, chronic prostatitis, excensis, arthritis, multiple sclerosis, psoriasis, sun burn, and periodontal disease, comprising the step of administering to said subject an effective amount of a composition according to claim 1.
- 23. The composition according to claim 1, wherein said histamine-1-receptor antagonist is diphenhydramine.
- 24. The composition according to claim 1, wherein said inflammatory disease is arthritis and said composition is designed for oral administration, comprising non-beying chondroitin sulfate, quercetin, D-glucosamine sulfate, and unrefined kernel olive oil.
- 25. The composition according to claim 9, comprising, in mg%, chondroitin suiface. 0.05; D-glucosamine sulfate, 0.05; quercetin, 0.03; and, unrefined kernel olive oil. 1-2.
- 26. The composition according to claim 1 for oral use in allergic conditions, comprising chondroitin sulfate, a flavonoid selected from the group consisting of quercetin, myricetin and knowpferol, and said kernel olive oil.
- 27. The composition according to claim 26, comprising 200 mg each of chondroitin sulfate and knowpferol and said kernel olive oil.
- 28. The composition according to claim 26, comprising chondroitin sulfate and myricetin and said kernel olive oil.
- 29. The composition according to claim 28, supplemented with a histamine-leave optor antagonist.
- 30. The composition according to claim 29, wherein said antagonist is diphenhydramine.
- 31. The composition according to claim 1, wherein said inflammatory disease is cancer and wherein said composition is designed for oral use, comprising 25-50 mg of genisse in and

7

Megible

(150-300 mg of quercetin, and said kernel olive oil.

- 32. The composition according to claim 1, wherein said inflammatory disease is atheroselerosis with or without myocardial ischemia, comprising 100-300 mg each of chondraitin sulfate, myricetin and S-adenosylmethionine, and said kernel olive oil, in a vehicle for oral use.
- 33. The composition according to claim 1, wherein said inflammatory disease is interstitial cysfitis, said composition comprising 100-300 mg of chondroitin sulfate. 100-300 mg of hyaluronic acid, and 200-400 mg quercetin, and said kernel olive oil, in a vehicle for oral use.
- 34. The composition according to claim 1, wherein said inflammatory disease is prostatitis, said composition comprising 100-200 mg of chondroitin sulfate, 100-200 mg hyaluronic acid and 200-400 mg of quercetin, and said kernel olive oil, in a vehicle for oral use.



Issue (Classification

Application No.	Applicant(s)
09/771.669	THEOHARIDES, THEOHARIS C.
Examiner	Art Unit
Sharon L. Howard	1615

	i IS	SUE CLASSIFICATION
ORIGINAL		CROSS REFERENCE(S)
CLASS SUBCLASS	CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)
514 886	424	49 464
INTERNATIONAL CLASSIFICATION	5/4	887 901
A01N 25/00		
A61K 2116		
Ala 1 K 9120		
Thurs Heward 7	19/04	Total Claims Allowed:
Negal Instruments Examiner)	A)64 Date)	Total Claims Allowed: TAIRMAN I PAGE NEW TRAIRMAN CENTER 1600 O.G. O.G. Print Claim(s) : Print Fig. SUPERVISORY (Date)

Claims renumbered in the same order as presented by applicant									ПС	PA		☐ T.D.			☐ R.1.47				
Final	Original		Final	Original		Final	Original		Final	Original		Final	Original		Final	Original		Final	Original
-	1			31	3 6 3 m 1 m 3 1 m 2 m 2 m		61			91)		121	27 ° 3 ' 4 1 4 7 ° 2 8		151			181
	2	33.A. 33		32			62			92			122	Ž.		152	7407 X		182
	3			33			63			93			123			153			183
	4	nA;		34			64			94			124			154			184
	5	y" ×		35	主義		65			95	i indik Carri		125			155			185
	6			36	100		66			96			126			156	() M		186
	7			37			67			97			127			157	[,,**]0		187
	8			38			68			98			128			158	27.72		188
	9			39			69			99			129			159			189
	10			40			70	14 T. 12		100			130			160			190
	11	268		41		•	71			101	May (S		131		L	161			191
-	12			42			72			102			132			162	2		192
	13	Na. ii 4		43			73			103			133			163			193
	14			44	NZ-E		74			104	114.3		134	1000		164	1.30		194
	15	200		45			75			105			135	2.8		165	\$55.X		195
	16	10.00		46	12/25		76			106			136	1	<u></u>	166			196
	17	学生		47			77			107	2. 28		137	Maria		167	10 to 11		197
	18			48			78			108			138			168			198
	19			49	Torris		79			109	i siyê		139			169			199
	20			50			80	100		110			140	100		170			200
	21			51			81			111		<u> </u>	141	Ĵaÿ.,		171			201
	22			52			82			112		L	142			172			202
	23			53] - 評餐		83	300		113			143	1 47		173			203
	24			54			84	فدانتا		114	2		144	1	 	174			204
	25			55].		85			115			145	3. P.		175		<u> </u>	205
	26]		56			86			116			146	#***		176		 	206
	27			57]:		87			117		<u> </u>	147			177		 	207
	28	1		58]. "		88	10 min # 10		118	政 主		148		<u> </u>	178		<u> </u>	208
	29			59] .		89			119			149	.	<u> </u>	179	J		209
	30	1.4		60	75.12		90	\$77.0		120	134.74	1	150			180	· · · · · · ·	L	210